表紙:大腸がん診断薬・治療薬の世界市場 - 成長・動向・予測
市場調査レポート
商品コード
353905

大腸がん診断薬・治療薬の世界市場 - 成長・動向・予測

Colorectal Cancer Diagnostics and Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 113 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円
大腸がん診断薬・治療薬の世界市場 - 成長・動向・予測
出版日: 2020年08月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 113 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の大腸がん向け診断薬および治療薬の市場について分析し、市場の基本構造や最新情勢、主な市場促進・抑制要因、市場規模の動向見通し (今後6年間分)、モダリティ (診断/治療法別) および地域別の詳細動向、市場競争の動き (各種資本取引など)、主要企業のプロファイルといった情報を取りまとめてお届けいたします。

第1章 イントロダクション

第2章 分析手法

第3章 エグゼクティブ・サマリー

第4章 市場のダイナミクス

  • 市場概要
  • 市場促進要因
  • 市場抑制要因
  • ポーターのファイブフォース分析

第5章 市場区分

  • モダリティ (手法) 別
    • 診断法
      • 検便
      • 免疫組織化学 (IHC)
      • 大腸内視鏡検査
      • 軟性S字結腸鏡検査
      • その他の診断法
    • 治療法
      • 化学療法
        • 代謝拮抗剤
          • フルオロウラシル
          • カペシタビン
        • アルキル化剤
          • オキサリプラチン
        • その他
      • 免疫療法
        • ベバシズマブ
        • セツキシマブ
        • パニツムマブ
      • がん防御物質
      • その他
  • 地域別
    • 北米 (米国、カナダ、メキシコなど)
    • 欧州 (ドイツ、英国、フランス、イタリア、スペインなど)
    • アジア太平洋地域 (中国、日本、インド、オーストラリア、韓国など)
    • 中東・アフリカ (湾岸協力会議 (GCC) 諸国、南アフリカなど)
    • 南米 (ブラジル、アルゼンチンなど)

第6章 競争環境

  • 企業プロファイル
    • Abbott Laboratories
    • Amgen Inc.
    • Clinical Genomics
    • EDP Biotech
    • Epigenomics AG
    • F. Hoffmann-La Roche AG
    • Novigenix SA
    • Quest Diagnostics
    • Sanofi SA
    • Siemens Healthineers
    • VolitionRX

第7章 市場機会と将来動向

目次
Product Code: 50590

The colorectal cancer diagnostics and therapeutics market is expected to register a CAGR of nearly 4.6% during the forecast period.

  • Colorectal cancer has one of the largest incidence and prevalence rates, worldwide. Primary causes of colorectal cancer are said to be lifestyle disorders, ageing, and diet.
  • According to the World Health Organization (WHO), an increase of around 70% is expected in the colorectal cancer cases across the world, by 2030.
  • Therefore, high incidence and prevalence rates are the primary factors, driving the market studied.
  • According to a research article published in 2016, "Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the United States".
  • Colorectal cancer (CRC) is estimated to account for over 9% of all cancer incidences and is a major cause of morbidity and mortality throughout the world. CRC is the second-most-common cause of cancer-related deaths in the United States.

Key Market Trends

Immunotherapy Expected to Remain a Significant Revenue Source For Leading Players Due to Label Expansions Despite Approaching Patent Expiry.

  • Immunotherapy refers to the fighting cancer cells by taking advantage of the human immune system. There are several immunotherapy drugs available for colorectal cancer worldwide. These therapeutics include targeted antibodies and checkpoint inhibitors.
  • s.Furthermore, growing R&D on combination therapy coupled with rising awareness on cancer therapeutics and advantages of immunotherapy anticipated fueling the segment growth over the forecast period.
  • For instance, In August 2018, United States Food and Drug Administration approved combination of immunotherapeutic drugs ipilimumab (Yervoy) and nivolumab (Opdivo) for the treatment of some patients with metastatic colorectal cancer who have been treated previously with standard chemotherapy drugs.
  • Moreover, the expansion of therapeutic applications of immunotherapeutic agents to colorectal cancer is projected to further fuel the market growth.

United States is Expected to Retain Largest Market Share During the Forecast Period

  • Geographically, the North Americacolorectal cancer diagnostics and therapeutics market projected to have significant market share with respect to demand and revenue.
  • In 2017, 39,910 new rectal cancer cases and 95,520 new colon cancer cases were reported in the United States based on the estimates by the American Cancer Society. These estimates indicate that colorectal cancer is increasing its prevalence in the United States, which is in turn, leading to the growth of the market.
  • Moreover, the Asia-Pacific colorectal cancer diagnostics and therapeutics market is also expected to witness a strong growth pattern in the coming years, with China and India showing rapid progress.
  • For instance, Chi-Med's Fruquintinob ha got approved for the treatment of colorectal cancer in China. This is expected to increase access to colorectal cancer therapeutics in China.

Competitive Landscape

Several large drug and equipment manufacturers exist within the global colorectal cancer diagnostic and therapeutics market. Moreover, several new biotech firms are also active in the therapeutics by launching new products participating in collaborations and acquisitions. Key players in the market include Abbott Laboratories, Epigenomics AG, F. Hoffmann-La Roche AG, Novigenix, and Siemens Healthineers among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Technological Advancements in Radiology and Chemotherapy
    • 4.2.2 Increasing Incidence and Prevalence of Colorectal Cancer
  • 4.3 Market Restraints
    • 4.3.1 High Costs and the Side Effects Associated with Drugs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Modality
    • 5.1.1 Diagnostics Techniques
      • 5.1.1.1 Stool Tests
      • 5.1.1.2 Immunohistochemistry
      • 5.1.1.3 Colonoscopy
      • 5.1.1.4 Flexible Sigmoidoscopy
      • 5.1.1.5 Other Diagnostics Techniques
    • 5.1.2 Therapeutics
      • 5.1.2.1 Chemotherapy
      • 5.1.2.2 Immunotherapy
      • 5.1.2.3 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East & Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East & Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Amgen Inc.
    • 6.1.3 Clinical Genomics
    • 6.1.4 EDP Biotech
    • 6.1.5 Epigenomics AG
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 Novigenix SA
    • 6.1.8 Quest Diagnostics
    • 6.1.9 Sanofi SA
    • 6.1.10 Siemens Healthineers
    • 6.1.11 VolitionRX

7 MARKET OPPORTUNITIES AND FUTURE TRENDS